Liu, Qi, et al. “Comparative Efficacy & Safety of Buparlisib Plus Fulvestrant, Fulvestrant Plus Dalpiciclib, and Ribociclib Plus Letrozole for Postmenopausal, Hormone Receptor-Positive, and HER2-Negative Breast Cancer”. Clinics, vol. 78, May 2023, p. 100291, https://doi.org/10.1016/.